| __timestamp | Neurocrine Biosciences, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 242549000 |
| Thursday, January 1, 2015 | 81491000 | 245098000 |
| Friday, January 1, 2016 | 94291000 | 147600000 |
| Sunday, January 1, 2017 | 121827000 | 264600000 |
| Monday, January 1, 2018 | 160524000 | 357900000 |
| Tuesday, January 1, 2019 | 200000000 | 1182600000 |
| Wednesday, January 1, 2020 | 275000000 | 357700000 |
| Friday, January 1, 2021 | 328100000 | 540100000 |
| Saturday, January 1, 2022 | 463800000 | 322900000 |
| Sunday, January 1, 2023 | 565000000 | 408000000 |
| Monday, January 1, 2024 | 731100000 |
Igniting the spark of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and Neurocrine Biosciences, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Neurocrine Biosciences, Inc. increased its R&D expenses by over 1,100%, starting from approximately $46 million in 2014 to a remarkable $565 million in 2023. This growth underscores their aggressive pursuit of new therapies. Meanwhile, United Therapeutics Corporation, with a more stable trajectory, saw a 68% increase in R&D spending, peaking at $1.18 billion in 2019.
These investments highlight the strategic focus of both companies on innovation, with Neurocrine's rapid growth suggesting a more aggressive expansion strategy compared to United Therapeutics' steady approach.
United Therapeutics Corporation or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
United Therapeutics Corporation or Grifols, S.A.: Who Invests More in Innovation?
Research and Development Investment: United Therapeutics Corporation vs Corcept Therapeutics Incorporated
R&D Spending Showdown: United Therapeutics Corporation vs Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Bausch Health Companies Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending